Pharmosa Biopharm (ROCO:6875) Shareholder Yield % : -1.16% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6875 Pharmosa Biopharm Inc ROCO:6875
27 GF Score
Price NT$33.00
GF Value NT$15.32
Valuation Significantly Overvalued
! 2 Warning Signs
View Full Analysis

What is Pharmosa Biopharm Shareholder Yield %?

Pharmosa Biopharm ROCO:6875 27 Shareholder Yield % is -1.16% as of Jun. 2026. GuruFocus rates ROCO:6875 with a GF Score™ of 27/100 and a GF Value™ of NT$15.32 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 1,285 Biotechnology companies, Pharmosa Biopharm ranks better than 53.39% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Pharmosa Biopharm's Shareholder Yield % was -1.16%.


Pharmosa Biopharm  (ROCO:6875) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Pharmosa Biopharm Shareholder Yield % Related Terms


Pharmosa Biopharm Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Pharmosa Biopharm's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Pharmosa Biopharm Shareholder Yield % Chart

Pharmosa Biopharm Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shareholder Yield %
Get a 7-Day Free Trial 0.00 -6.87 -4.50 -14.10 0.25

Pharmosa Biopharm Quarterly Data
Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.41 0.34 0.25 0.26 -0.99

ROCO:6875 vs VRTX, REGN, RVMD: Shareholder Yield % Comparison

For the Biotechnology subindustry, Pharmosa Biopharm's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pharmosa Biopharm Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharmosa Biopharm's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Pharmosa Biopharm's Shareholder Yield % falls into.


ROCO:6875
27GF Score
Pharmosa Biopharm Inc ROCO:6875
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Pharmosa Biopharm Shareholder Yield % Calculation

Pharmosa Biopharm's Shareholder Yield % for the quarter that ended in Jun. 2026 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-0.01 %+-0.98 %
=-0.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -1.16% mean?
Pharmosa Biopharm (ROCO:6875) has a Shareholder Yield % of -1.16% as of Jun. 2026. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Pharmosa Biopharm and its competitors. According to the industry distribution chart, Pharmosa Biopharm ranks #599 out of 1285 companies in the Biotechnology industry, placing it in the top 46.6%.
Is Pharmosa Biopharm's Shareholder Yield % too high?
Pharmosa Biopharm's current Shareholder Yield % is -1.16%. Based on the distribution chart, Pharmosa Biopharm ranks #599 out of 1285 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Pharmosa Biopharm has a GF Score™ of 27/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Pharmosa Biopharm's Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharmosa Biopharm ranks #599 out of 1285 companies for Shareholder Yield %. This puts Pharmosa Biopharm in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Pharmosa Biopharm and its competitors. Pharmosa Biopharm's current Shareholder Yield % is -1.16%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmosa Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Pharmosa Biopharm (ROCO:6875) is currently considered Significantly Overvalued. The stock's GF Value™ is NT$15.32, compared to a current price of NT$33.00 — trading 115.4% above its estimated fair value. The current Shareholder Yield % is -1.16%. Pharmosa Biopharm's overall GF Score™ is 27/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Pharmosa Biopharm (ROCO:6875), the current Shareholder Yield % is -1.16% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharmosa Biopharm (ROCO:6875) Overvalued in 2026?

Based on GuruFocus' analysis, Pharmosa Biopharm stock appears to be overvalued. The current stock price of NT$33.00 is trading 115.4% above its estimated GF Value™ of NT$15.32. GuruFocus considers Pharmosa Biopharm to be Significantly Overvalued.

Key valuation signals for ROCO:6875:

  • Shareholder Yield %: -1.16%
  • GF Value™: NT$15.32 vs. price of NT$33.00 (115.4% above fair value)
  • GF Score™: 27/100 with 2 warning signs

No single metric tells the full story. See the ROCO:6875 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Pharmosa Biopharm Business Description

Address No. 508, Sec. 7, Zhongxiao E. Road, 11th Floor / 11th Floor-1, Nangang District, Taipei, TWN
Pharmosa Biopharm Inc is a world-class biotechnology company. The Company's principal business activities comprise the development and commercialization of inventive biopharmaceutical drugs. Its product portfolio includes sustained-release dosage forms and drug-device combination products intended for home based therapies.
27GF Score

Get the complete analysis for ROCO:6875

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$33.00
Price
NT$15.32
GF Value